Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC By Ogkologos - June 30, 2026 98 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HARMONi-6 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Why People With Cancer Need to Be Taking Care of Their... August 27, 2020 Mom Is Outraged After Finding Out Her Mother-In-Law Changed The Baby’s... May 6, 2019 NHL Player Carey Price Surprises 11-Year-Old Boy Who Just Lost Mom... June 24, 2019 Crazy Bride Called Off Her Wedding Because Her Guests Refused To... April 22, 2019 Load more HOT NEWS Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,... Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma
